Paris - Delayed Quote EUR

Innate Pharma S.A. (IPH.PA)

Compare

1.8700

-0.0240

(-1.27%)

At close: October 18 at 5:35 PM GMT+2

Currency in EUR All numbers in thousands

Download

Breakdown

TTM

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

Total Revenue

51,901.0000

49,580.0000

12,110.0000

56,155.0000

Cost of Revenue

3,042.0000

45,158.0000

Gross Profit

53,791.0000

23,815.0000

Operating Expense

64,570.0000

66,005.0000

59,937.0000

55,076.0000

Operating Income

-12,669.0000

-16,425.0000

-47,827.0000

1,079.0000

Net Non Operating Interest Income Expense

2,537.0000

258.0000

15.0000

223.0000

Other Income Expense

2,562.0000

-41,805.0000

2,330.0000

-2,131.0000

Pretax Income

-7,570.0000

-57,972.0000

-45,478.0000

-829.0000

Net Income Common Stockholders

-7,570.0000

-58,103.0000

-52,809.0000

-63,984.0000

Diluted NI Available to Com Stockholders

-7,570.0000

-58,103.0000

-52,809.0000

-63,984.0000

Basic EPS

-0.09

-0.73

-0.66

-0.81

Diluted EPS

-0.09

-0.73

-0.66

-0.81

Basic Average Shares

80,453.2820

84,111.1110

79,639.8260

79,542.6270

78,934.9600

Diluted Average Shares

80,453.2820

84,111.1110

79,639.8260

79,542.6270

78,934.9600

Total Operating Income as Reported

-12,669.0000

-57,425.0000

-47,825.0000

1,079.0000

Rent Expense Supplemental

1,702.0000

1,872.0000

Total Expenses

64,570.0000

66,005.0000

59,937.0000

55,076.0000

Net Income from Continuing & Discontinued Operation

-7,570.0000

-58,103.0000

-52,809.0000

-63,984.0000

Normalized Income

-10,132.0000

-16,167.0000

-47,808.0000

1,302.0000

Interest Income

3,177.0000

546.0000

327.0000

564.0000

Interest Expense

640.0000

288.0000

312.0000

341.0000

Net Interest Income

2,537.0000

258.0000

15.0000

223.0000

EBIT

-6,930.0000

-57,684.0000

-45,166.0000

-488.0000

EBITDA

-1,839.0000

-12,279.0000

-40,570.0000

56,309.0000

Reconciled Cost of Revenue

3,042.0000

45,160.0000

Reconciled Depreciation

5,091.0000

45,405.0000

4,596.0000

56,797.0000

Net Income from Continuing Operation Net Minority Interest

-7,570.0000

-57,972.0000

-45,478.0000

-829.0000

Total Unusual Items Excluding Goodwill

2,562.0000

-41,805.0000

2,330.0000

-2,131.0000

Total Unusual Items

2,562.0000

-41,805.0000

2,330.0000

-2,131.0000

Normalized EBITDA

-4,401.0000

29,526.0000

-42,900.0000

58,440.0000

12/31/2019 - 11/1/2006

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

ALCLS.PA Cellectis S.A.

1.8360

+0.44%

GNRO.PA GeNeuro SA

0.0828

+7.25%

AELIS.PA Aelis Farma SA

3.6000

-8.63%

NANO.PA Nanobiotix S.A.

4.4800

+1.40%

ADOC.PA Adocia SA

7.49

+21.00%

KDEV.ST Karolinska Development AB (publ)

1.2760

+4.25%

PHXM.PA PHAXIAM Therapeutics S.A.

1.7600

-2.11%

CYAD.BR Celyad Oncology SA

0.2525

-0.98%

HPHA.DE Heidelberg Pharma AG

2.6700

+4.71%

GNFT.PA Genfit S.A.

5.33

-6.49%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Innate Pharma S.A. (IPH.PA)

Upgrade to begin using 40 years of financial statements and get so much more.

Related Tickers